Thank you, and hopefully you will.
Dr. Henry, I'll continue where I was before.
Certainly, I think the concern with Dilaudid is that it has become a kind of entry-level narcotic in Vancouver because it's cheap. My understanding in talking to people who work in the community is that the price of one Dilaudid tablet was $20 before safe supply. Now it's a dollar. As one psychiatrist said that he asks his kids who are on Dilaudid, “Why Dilaudid?”, and they say that, on the street, it's five bucks to buy a joint whereas they can get five Dilaudid for the same price, so which are you going to do?
Certainly, the concern is that you start off with Dilaudid and because, as you know, with narcotics, once you get used to it, you get tolerant, you have to go to something stronger to get the same kind of buzz, so they're switching over to fentanyl. Certainly, one psychiatrist who works with that population told me that of the kids he knows who are on [Technical difficulty—Editor], it's half on Dilaudid and half started originally on Dilaudid.
Certainly, there's the concern around safe supply. I don't know if you want to comment on that. I think that the Nguyen article in JAMA certainly suggested there was perhaps a societal harm that coincided with safe supply.
I don't know if you want to comment on that, but I want to go to the second part of the question, which is that there is good evidence for IOAT, intravenous opioid agonist treatment, the kind of Swiss model where people who are hard-core users are given heroin to use intravenously.